A novel synthetic compound overcomes drug resistance on EGFR (T790M) and cancer stemness in human non-small cell lung cancer

被引：0
|
作者：
Pan, Pei Ying [1 ]
Chang, Chien-Jen [2 ]
Liu, Kuang-Kai [2 ]
Chan, Yu-Chi [2 ]
Chen, Yan-Ting [2 ]
Chao, Jui-I [2 ]
机构：
[1] Natl Chiao Tung Univ, Bioinformat & Syst Biol, Hsinchu, Taiwan
[2] Natl Chiao Tung Univ, Hsinchu, Taiwan
来源：
FASEB JOURNAL | 2017年 / 31卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
lb181
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer
    Koo, Hyun Jung
    Kim, Mi Young
    Park, Sojung
    Lee, Han Na
    Kim, Hwa Jung
    Lee, Jae Cheol
    Kim, Sang-We
    Lee, Dae Ho
    Choi, Chang-Min
    RADIOLOGY, 2018, 289 (01) : 227 - 237
  • [22] Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer
    Lee, Eun Hye
    Kwak, Se Hyun
    Kim, Kyeong Yeon
    Kim, Chi Young
    Lee, Sang Hoon
    Heo, Seok-Jae
    Chang, Yoon Soo
    Kim, Eun Young
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [23] The cis/trans effect of the T790M drug resistant mutation in non-small cell lung cancer
    Umelo, I.
    Chen, G.
    Teugels, E.
    De Grève, J.
    EJC SUPPLEMENTS, 2010, 8 (07): : 68 - 68
  • [24] An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer
    Wang, Jingyi
    Wu, Lin
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (06) : 647 - 652
  • [25] Differential efficacy of Osimertinib in EGFR T790M positive non-small cell lung cancer by metastatic site
    Uematsu, Shinya
    ANNALS OF ONCOLOGY, 2019, 30 : 109 - 109
  • [26] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [27] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
  • [28] TGFa upregulation mediates growth retardation in EGFR T790M mutant non-small cell lung cancer
    Repellin, Claire E.
    Eser, Pinar O.
    Capelletti, Marzia
    Shimamura, Takeshi
    Ercan, Dalia
    Xu, Chunxiao
    Gray, Nathanael S.
    Wong, Kwok-Kin
    Janne, Pasi A.
    CANCER RESEARCH, 2016, 76
  • [29] AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
    Ren Zhao
    Shun Zhou
    Bing Xia
    Cui-ying Zhang
    Ping Hai
    Hong Zhe
    Yan-yang Wang
    BMC Cancer, 16
  • [30] Clinicopathological Characteristics of Non-small Cell Lung Cancer Patients With Primary Concomitant EGFR T790M Mutation
    Li, Hang
    Wang, Rui
    Hu, Haichuan
    Pan, Yunjian
    Wang, Lei
    Zhang, Yang
    Sun, Yihua
    Chen, Haiquan
    CHEST, 2014, 145 (03)
12345